339 related articles for article (PubMed ID: 19157547)
1. Monitoring minimal residual disease with flow cytometry, antigen-receptor gene rearrangements and fusion transcript quantification in Philadelphia-positive childhood acute lymphoblastic leukemia.
Thörn I; Botling J; Hermansson M; Lönnerholm G; Sundström C; Rosenquist R; Barbany G
Leuk Res; 2009 Aug; 33(8):1047-54. PubMed ID: 19157547
[TBL] [Abstract][Full Text] [Related]
2. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
3. Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia.
Chen JS; Hsiao CC; Sheen JM; Cheng CN
Leuk Res; 2007 Oct; 31(10):1351-7. PubMed ID: 17445885
[TBL] [Abstract][Full Text] [Related]
4. Applicability of IG/TCR gene rearrangements as targets for minimal residual disease assessment in a population-based cohort of Swedish childhood acute lymphoblastic leukaemia diagnosed 2002-2006.
Thörn I; Forestier E; Thuresson B; Wasslavik C; Malec M; Li A; Lindström-Eriksson E; Botling J; Barbany G; Jacobsson S; Olofsson T; Porwit A; Sundström C; Rosenquist R
Eur J Haematol; 2010 Feb; 84(2):117-27. PubMed ID: 19895569
[TBL] [Abstract][Full Text] [Related]
5. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
6. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.
Boeckx N; Willemse MJ; Szczepanski T; van der Velden VH; Langerak AW; Vandekerckhove P; van Dongen JJ
Leukemia; 2002 Mar; 16(3):368-75. PubMed ID: 11896540
[TBL] [Abstract][Full Text] [Related]
7. [Tandem application of flow cytometry and polymerase chain reaction for choice targets of minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Jiang LM; Zhao JC; Chen J; Pan C; Dong L; Chen J; Xue HL; Tang JY; Wang YP
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Apr; 11(4):246-50. PubMed ID: 19374803
[TBL] [Abstract][Full Text] [Related]
8. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.
Kerst G; Kreyenberg H; Roth C; Well C; Dietz K; Coustan-Smith E; Campana D; Koscielniak E; Niemeyer C; Schlegel PG; Müller I; Niethammer D; Bader P
Br J Haematol; 2005 Mar; 128(6):774-82. PubMed ID: 15755280
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
[TBL] [Abstract][Full Text] [Related]
10. Lack of clinical utility of minimal residual disease detection in allogeneic stem cell recipients with childhood acute lymphoblastic leukemia: multi-institutional collaborative study in Japan.
Imashuku S; Terui K; Matsuyama T; Asami K; Tsuchiya S; Ishii E; Kawa K; Kosaka Y; Eguchi H; Tsuchida M; Ikuta K; Kato S; Koizumi S; Okamura J; Morimoto A; Hibi S; Hamaoka K;
Bone Marrow Transplant; 2003 Jun; 31(12):1127-35. PubMed ID: 12796792
[TBL] [Abstract][Full Text] [Related]
11. Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring.
Zaliova M; Fronkova E; Krejcikova K; Muzikova K; Mejstrikova E; Stary J; Trka J; Zuna J
Leukemia; 2009 May; 23(5):944-51. PubMed ID: 19158828
[TBL] [Abstract][Full Text] [Related]
12. WT1 protein expression in childhood acute leukemia.
Kerst G; Bergold N; Gieseke F; Coustan-Smith E; Lang P; Kalinova M; Handgretinger R; Trka J; Müller I
Am J Hematol; 2008 May; 83(5):382-6. PubMed ID: 18161786
[TBL] [Abstract][Full Text] [Related]
13. Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome.
Chen ZX; Kaeda J; Saunders S; Goldman JM
Chin Med J (Engl); 2004 Jul; 117(7):968-71. PubMed ID: 15265366
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
[TBL] [Abstract][Full Text] [Related]
15. Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia.
Robillard N; Cavé H; Méchinaud F; Guidal C; Garnache-Ottou F; Rohrlich PS; Avet-Loiseau H; Garand R
Haematologica; 2005 Nov; 90(11):1516-23. PubMed ID: 16266899
[TBL] [Abstract][Full Text] [Related]
16. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
[TBL] [Abstract][Full Text] [Related]
17. Detection of minimal residual disease in acute leukemia.
van der Velden VH; Boeckx N; van Wering ER; van Dongen JJ
J Biol Regul Homeost Agents; 2004; 18(2):146-54. PubMed ID: 15471219
[TBL] [Abstract][Full Text] [Related]
18. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
[TBL] [Abstract][Full Text] [Related]
19. CD66c expression in B-cell acute lymphoblastic leukemia: strength and weakness.
Guillaume N; Penther D; Vaida I; Gruson B; Harrivel V; Claisse JF; Capiod JC; Lefrere JJ; Damaj G
Int J Lab Hematol; 2011 Feb; 33(1):92-6. PubMed ID: 20666852
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.
Ryan J; Quinn F; Meunier A; Boublikova L; Crampe M; Tewari P; O'Marcaigh A; Stallings R; Neat M; O'Meara A; Breatnach F; McCann S; Browne P; Smith O; Lawler M
Br J Haematol; 2009 Jan; 144(1):107-15. PubMed ID: 19016726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
